ONCC Practice Tests (OCN - Treatment
Modalities) Questions and Answers
1. A patient demonstrates an adequate understanding of the teaching
provided regarding chemotherapy and myelosuppression by stating:
"Myelosuppression is:
a potential side effect of many cancer treatments."
unintentional prior to a bone marrow transplant."
when laboratory values show an elevation in the white blood cell
count." the overreaction of the body's immune system to a medication.": a
potential side
effect of many cancer treatments."
Answer: Chemotherapy will decrease the response by the immune system by causing neutropenia,
anemia, and thrombocytopenia, collectively known as myelosuppression.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014). Chemotherapy and biotherapy
guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology Nursing Society, p.
171.
2. Alkylating agents exert their effects by:
binding to DNA strands, preventing DNA replication and cell division.
,causing the release of toxic free radicals inside the cell, triggering cell
apoptosis.
attaching to CD52 on the surface of B and T cells, resulting in
antibody-de-pendent lysis.
disrupting folate-dependent metabolic processes essential for cell
replication.: binding to DNA strands, preventing DNA replication and cell division.
Answer: Alkalyting agents break the DNA helix strand and interfere with DNA replication.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014). Chemotherapy and biotherapy
guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology Nursing Society, p.
27(t).
3. The nurse preparing to instill intravesical mitomycin should wear
which of the following pieces of personal protective equipment?
A plastic face shield
A pair of shoe
covers
A front-closing laboratory gown
One pair of powdered nitrile gloves: A plastic face shield
Answer: A plastic face shield should be used when splashing of hazardous drugs is possible.
Intravesical administration carries a risk of splashing.
Reference: Polovich, M. (2017). Safe handling of hazardous drugs (3rd ed.). Pittsburgh, PA: Oncology
Nursing Society,
, p. 27.
4. Adjuvant therapy for breast cancer is administered:
after primary therapy to increase the chance of long-term, disease-free
sur-vival.
before primary therapy to shrink a tumor that is inoperable in its
current state.
at any time during therapy to cure the patient and kill cancer cells.
to locally treat cancer with minimal harm to normal cells.: after primary therapy
to
increase the chance of long-term, disease-free survival.
Answer: The goal of adjuvant therapy is to target minimal, residual disease for patients at high risk of
developing metastasis.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014). Chemotherapy and biotherapy
guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology Nursing Society, p.
5.
5. Hormone therapy is effective for which two types of cancer?
Breast and prostate
Sarcoma and small cell
lung Lymphoma and
Modalities) Questions and Answers
1. A patient demonstrates an adequate understanding of the teaching
provided regarding chemotherapy and myelosuppression by stating:
"Myelosuppression is:
a potential side effect of many cancer treatments."
unintentional prior to a bone marrow transplant."
when laboratory values show an elevation in the white blood cell
count." the overreaction of the body's immune system to a medication.": a
potential side
effect of many cancer treatments."
Answer: Chemotherapy will decrease the response by the immune system by causing neutropenia,
anemia, and thrombocytopenia, collectively known as myelosuppression.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014). Chemotherapy and biotherapy
guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology Nursing Society, p.
171.
2. Alkylating agents exert their effects by:
binding to DNA strands, preventing DNA replication and cell division.
,causing the release of toxic free radicals inside the cell, triggering cell
apoptosis.
attaching to CD52 on the surface of B and T cells, resulting in
antibody-de-pendent lysis.
disrupting folate-dependent metabolic processes essential for cell
replication.: binding to DNA strands, preventing DNA replication and cell division.
Answer: Alkalyting agents break the DNA helix strand and interfere with DNA replication.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014). Chemotherapy and biotherapy
guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology Nursing Society, p.
27(t).
3. The nurse preparing to instill intravesical mitomycin should wear
which of the following pieces of personal protective equipment?
A plastic face shield
A pair of shoe
covers
A front-closing laboratory gown
One pair of powdered nitrile gloves: A plastic face shield
Answer: A plastic face shield should be used when splashing of hazardous drugs is possible.
Intravesical administration carries a risk of splashing.
Reference: Polovich, M. (2017). Safe handling of hazardous drugs (3rd ed.). Pittsburgh, PA: Oncology
Nursing Society,
, p. 27.
4. Adjuvant therapy for breast cancer is administered:
after primary therapy to increase the chance of long-term, disease-free
sur-vival.
before primary therapy to shrink a tumor that is inoperable in its
current state.
at any time during therapy to cure the patient and kill cancer cells.
to locally treat cancer with minimal harm to normal cells.: after primary therapy
to
increase the chance of long-term, disease-free survival.
Answer: The goal of adjuvant therapy is to target minimal, residual disease for patients at high risk of
developing metastasis.
Reference: Polovich, M., Olsen, M., & LeFebvre, K. (Eds.). (2014). Chemotherapy and biotherapy
guidelines and recommendations for practice (4th ed.). Pittsburgh, PA: Oncology Nursing Society, p.
5.
5. Hormone therapy is effective for which two types of cancer?
Breast and prostate
Sarcoma and small cell
lung Lymphoma and
